{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:16:01Z","timestamp":1793718961315,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010580","name":"Department of Science and Technology, Hubei Provincial People's Government","doi-asserted-by":"publisher","award":["Q201810"],"award-info":[{"award-number":["Q201810"]}],"id":[{"id":"10.13039\/501100010580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06461-y","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:21:24Z","timestamp":1745594484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review"],"prefix":"10.1186","volume":"23","author":[{"given":"Haifeng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Davoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Sadegh-Nejadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molood","family":"Bagherieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-118X","authenticated-orcid":false,"given":"Reza","family":"Afrisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"6461_CR1","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.","journal-title":"Front Endocrinol"},{"key":"6461_CR2","unstructured":"Cavan D, da Rocha Fernandes J, Makaroff L, Ogurtsova K, Webber S. IDF diabetes atlas, Brussels: International Diabetes Federation. ISBN 978-2-930229-81-2; 2015."},{"key":"6461_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fendo.2019.00496","volume":"10","author":"A Arp\u00f3n","year":"2019","unstructured":"Arp\u00f3n A, Milagro FI, Santos JL, Garc\u00eda-Granero M, Riezu-Boj J-I, Mart\u00ednez JA. Interaction among sex, aging, and epigenetic processes concerning visceral fat, insulin resistance, and dyslipidaemia. Front Endocrinol. 2019;10:496.","journal-title":"Front Endocrinol"},{"issue":"7","key":"6461_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S2213-8587(15)00127-8","volume":"3","author":"JC Chambers","year":"2015","unstructured":"Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes Endocrinol. 2015;3(7):526\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6461_CR5","doi-asserted-by":"publisher","first-page":"1143067","DOI":"10.3389\/fendo.2023.1143067","volume":"14","author":"A Mansour","year":"2023","unstructured":"Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular and macrovascular complications of type 2 diabetes mellitus: exome wide association analyses. Front Endocrinol. 2023;14:1143067.","journal-title":"Front Endocrinol"},{"issue":"5","key":"6461_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Reviews Endocrinol. 2019;15(5):288\u201398.","journal-title":"Nat Reviews Endocrinol"},{"key":"6461_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14290","volume":"23","author":"S Sarma","year":"2021","unstructured":"Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metabolism. 2021;23:3\u201316.","journal-title":"Diabetes Obes Metabolism"},{"issue":"3","key":"6461_CR8","first-page":"e00330","volume":"5","author":"M Bl\u00fcher","year":"2022","unstructured":"Bl\u00fcher M, Ceriello A, Davies M, Rodbard H, Sattar N, Schnell O, et al. Managing weight and glycaemic targets in people with type 2 diabetes\u2014How Far have we come? Endocrinology. Diabetes Metab. 2022;5(3):e00330.","journal-title":"Diabetes Metab"},{"issue":"2","key":"6461_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0020-7292(01)00477-5","volume":"75","author":"S Weerakiet","year":"2001","unstructured":"Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynecol Obstet. 2001;75(2):177\u201384.","journal-title":"Int J Gynecol Obstet"},{"issue":"4","key":"6461_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dci16-0042","volume":"40","author":"P Palta","year":"2017","unstructured":"Palta P, Huang ES, Kalyani RR, Golden SH, Yeh H-C. Hemoglobin A1c and mortality in older adults with and without diabetes: results from the National health and nutrition examination surveys (1988\u20132011). Diabetes Care. 2017;40(4):453\u201360.","journal-title":"Diabetes Care"},{"key":"6461_CR11","unstructured":"Rothberg AE, Ard JD, Gudzune KA, Herman WH. Obesity management for the treatment of type 2 diabetes. Diabetes in America [Internet]. 2024."},{"issue":"3","key":"6461_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen MR, Doran E, Halestrap AP. Evidence that Metformin exerts its anti-diabetic effects through Inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(3):607\u201314.","journal-title":"Biochem J"},{"key":"6461_CR13","doi-asserted-by":"crossref","unstructured":"Malboosbaf R, Hatami N. Treatment Approaches and Challenges. Nanoscience Applications in Diabetes Treatment. 2023:31.","DOI":"10.2174\/9789815196535123010005"},{"issue":"Supplement1","key":"6461_CR14","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.2337\/dc21-S008","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(Supplement1):S100\u201310.","journal-title":"Diabetes Care"},{"key":"6461_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3389\/fendo.2018.00719","volume":"9","author":"B Capuani","year":"2018","unstructured":"Capuani B, Pacifici F, Della-Morte D, Lauro D. Glucagon like peptide 1 and MicroRNA in metabolic diseases: focusing on GLP1 action on MiRNAs. Front Endocrinol. 2018;9:719.","journal-title":"Front Endocrinol"},{"issue":"Suppl 2","key":"6461_CR16","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279.","journal-title":"Diabetes Care"},{"key":"6461_CR17","doi-asserted-by":"crossref","unstructured":"Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Diabetes-Perspectives Drug Therapy. 2011:53\u201374.","DOI":"10.1007\/978-3-642-17214-4_3"},{"issue":"3","key":"6461_CR18","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1111\/j.1755-5922.2010.00256.x","volume":"30","author":"T Okerson","year":"2012","unstructured":"Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146\u201355.","journal-title":"Cardiovasc Ther"},{"issue":"15","key":"6461_CR19","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580\u201391.","journal-title":"JAMA"},{"issue":"6","key":"6461_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1530\/EJE-09-0101","volume":"160","author":"M Monami","year":"2009","unstructured":"Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909\u201317.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"6461_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","volume":"17","author":"M Movahednasab","year":"2025","unstructured":"Movahednasab M, Dianat-Moghadam H, Khodadad S, Nedaeinia R, Safabakhsh S, Ferns G, et al. GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation. Diabetol Metab Syndr. 2025;17(1):60.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"6461_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3111\/13696998.2012.679756","volume":"15","author":"L-A Miller","year":"2012","unstructured":"Miller L-A, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, et al. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ. 2012;15(4):746\u201357.","journal-title":"J Med Econ"},{"key":"6461_CR23","doi-asserted-by":"publisher","first-page":"1483792","DOI":"10.3389\/fphar.2024.1483792","volume":"15","author":"X He","year":"2025","unstructured":"He X, Zhao W, Li P, Zhang Y, Li G, Su H, et al. Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus. Front Pharmacol. 2025;15:1483792.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6461_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13098-025-01581-3","volume":"17","author":"X Miao","year":"2025","unstructured":"Miao X, Davoudi M, Alitotonchi Z, Ahmadi ES, Amraee F, Alemi A, et al. Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through MicroRNA regulation linked to glucagon-like peptide-1 receptor agonists. Diabetol Metab Syndr. 2025;17(1):13.","journal-title":"Diabetol Metab Syndr"},{"key":"6461_CR25","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. 2019."},{"key":"6461_CR26","doi-asserted-by":"publisher","first-page":"106411","DOI":"10.1016\/j.phrs.2022.106411","volume":"184","author":"L El Eid","year":"2022","unstructured":"El Eid L, Reynolds CA, Tomas A, Jones B. Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics. Pharmacol Res. 2022;184:106411.","journal-title":"Pharmacol Res"},{"key":"6461_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","volume":"71","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Pir\u0161 B, Gori\u010dar K, Dol\u017ean V, Jane\u017e A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight Lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71:817\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"6461_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13098-022-00963-1","volume":"14","author":"P Luo","year":"2022","unstructured":"Luo P, Fan Y, Xiong Y, Feng H, Yang Z, Zhang C, et al. Genetic variants of the GLP-1R gene affect the susceptibility and glucose metabolism of gestational diabetes mellitus: a two-center nested case\u2013control study. Diabetol Metab Syndr. 2022;14(1):190.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"6461_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2478\/jomb-2018-0009","volume":"37","author":"\u0130H Demirsoy","year":"2018","unstructured":"Demirsoy \u0130H, Ertural DY, Balci \u015e, \u00c7\u0131nk\u0131r \u00dc, Sezer K, Tamer L, et al. Profiles of Circulating MiRNAs following Metformin treatment in patients with type 2 diabetes. J Med Biochem. 2018;37(4):499.","journal-title":"J Med Biochem"},{"key":"6461_CR30","doi-asserted-by":"crossref","unstructured":"Catanzaro G, Besharat ZM, Chiacchiarini M, Abballe L, Sabato C, Vacca A et al. Circulating microRNAs in elderly type 2 diabetic patients. International Journal of Endocrinology. 2018;2018.","DOI":"10.1155\/2018\/6872635"},{"issue":"9","key":"6461_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.metabol.2015.05.013","volume":"64","author":"E Flowers","year":"2015","unstructured":"Flowers E, Aouizerat BE, Abbasi F, Lamendola C, Grove KM, Fukuoka Y, et al. Circulating microRNA-320a and microRNA-486 predict Thiazolidinedione response: moving towards precision health for diabetes prevention. Metabolism. 2015;64(9):1051\u20139.","journal-title":"Metabolism"},{"key":"6461_CR32","doi-asserted-by":"publisher","first-page":"251686572211300","DOI":"10.1177\/25168657221130041","volume":"15","author":"P Palihaderu","year":"2022","unstructured":"Palihaderu P, Mendis B, Premarathne J, Dias W, Yeap SK, Ho WY, et al. Therapeutic potential of MiRNAs for type 2 diabetes mellitus: an overview. Epigenetics Insights. 2022;15:25168657221130041.","journal-title":"Epigenetics Insights"},{"issue":"1","key":"6461_CR33","doi-asserted-by":"publisher","first-page":"20230873","DOI":"10.1515\/med-2023-0873","volume":"18","author":"F Lu","year":"2023","unstructured":"Lu F, Gong H, Duan L, Yan Y, Chen L, Peng P, et al. miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD. Open Med. 2023;18(1):20230873.","journal-title":"Open Med"},{"issue":"1","key":"6461_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2337\/dbi15-0028","volume":"65","author":"MV Joglekar","year":"2016","unstructured":"Joglekar MV, Januszewski AS, Jenkins AJ, Hardikar AA. Circulating MicroRNA biomarkers of diabetic retinopathy. Diabetes. 2016;65(1):22\u20134.","journal-title":"Diabetes"},{"issue":"17","key":"6461_CR35","doi-asserted-by":"publisher","first-page":"9454","DOI":"10.3390\/ijms22179454","volume":"22","author":"C Formichi","year":"2021","unstructured":"Formichi C, Fignani D, Nigi L, Grieco GE, Brusco N, Licata G, et al. Circulating MicroRNAs signature for predicting response to GLP1-RA therapy in type 2 diabetic patients: a pilot study. Int J Mol Sci. 2021;22(17):9454.","journal-title":"Int J Mol Sci"},{"key":"6461_CR36","doi-asserted-by":"crossref","unstructured":"Yadav P, Tamilselvan R, Harita M, Singh KK. MicroRNA-mediated regulation of nonsense-mediated mRNA decay factors: Insights into microRNA prediction tools and profiling techniques. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2024:195022.","DOI":"10.1016\/j.bbagrm.2024.195022"},{"key":"6461_CR37","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.phrs.2020.104662","volume":"153","author":"S Radbakhsh","year":"2020","unstructured":"Radbakhsh S, Sathyapalan T, Banach M, Sahebkar A. Incretins and MicroRNAs: interactions and physiological relevance. Pharmacol Res. 2020;153:104662.","journal-title":"Pharmacol Res"},{"issue":"10","key":"6461_CR38","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/ijms17101712","volume":"17","author":"C Catalanotto","year":"2016","unstructured":"Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6461_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41580-021-00354-w","volume":"22","author":"P Agbu","year":"2021","unstructured":"Agbu P, Carthew RW. MicroRNA-mediated regulation of glucose and lipid metabolism. Nat Rev Mol Cell Biol. 2021;22(6):425\u201338.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6461_CR40","doi-asserted-by":"crossref","unstructured":"Al-Noshokaty TM, Abdelhamid R, Abdelmaksoud NM, Khaled A, Hossam M, Ahmed R et al. Unlocking the multifaceted roles of GLP-1: physiological functions and therapeutic potential. Toxicol Rep. 2025:101895.","DOI":"10.1016\/j.toxrep.2025.101895"},{"issue":"6","key":"6461_CR41","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1002\/ctm2.468","volume":"11","author":"X He","year":"2021","unstructured":"He X, Kuang G, Wu Y, Ou C. Emerging roles of Exosomal MiRNAs in diabetes mellitus. Clin Translational Med. 2021;11(6):e468.","journal-title":"Clin Translational Med"},{"key":"6461_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0823-z","volume":"17","author":"R Zhou","year":"2018","unstructured":"Zhou R, Chen KK, Zhang J, Xiao B, Huang Z, Ju C, et al. The decade of Exosomal long RNA species: an emerging cancer antagonist. Mol Cancer. 2018;17:1\u201314.","journal-title":"Mol Cancer"},{"issue":"3","key":"6461_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s13105-024-01026-x","volume":"80","author":"T Lu","year":"2024","unstructured":"Lu T, Zheng Y, Chen X, Lin Z, Liu C, Yuan C. The role of exosome derived MiRNAs in inter-cell crosstalk among insulin-related organs in type 2 diabetes mellitus. J Physiol Biochem. 2024;80(3):501\u201310.","journal-title":"J Physiol Biochem"},{"issue":"24","key":"6461_CR44","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.7150\/thno.49168","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Nie H, He X, Liao Z, Zhou Y, Zhou J, et al. The emerging role of super enhancer-derived noncoding RNAs in human cancer. Theranostics. 2020;10(24):11049.","journal-title":"Theranostics"},{"issue":"3","key":"6461_CR45","doi-asserted-by":"publisher","first-page":"pbae021","DOI":"10.1093\/pcmedi\/pbae021","volume":"7","author":"YL Sou","year":"2024","unstructured":"Sou YL, Chilian WM, Ratnam W, Zain SM, Syed Abdul Kadir SZ, Pan Y, et al. Exosomal MiRNAs and IsomiRs: potential biomarkers for type 2 diabetes mellitus. Precision Clin Med. 2024;7(3):pbae021.","journal-title":"Precision Clin Med"},{"key":"6461_CR46","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"6461_CR47","unstructured":"Nikolic D, Giglio R, Chianetta R, Castracani CC, Sardo V, Castellino G, et al. editors. The GLP-1RA exenatide LAR increases circulating miR-27b in patients with type 2 diabetes: an 8-month prospective study of cardiometabolic and epigenetic response. DIABETOLOGIA; 2017: SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA."},{"issue":"4","key":"6461_CR48","doi-asserted-by":"publisher","first-page":"e1549","DOI":"10.1210\/clinem\/dgz069","volume":"105","author":"B Gaborit","year":"2020","unstructured":"Gaborit B, Julla J-B, Besbes S, Proust M, Vincentelli C, Alos B, et al. Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe type 2 diabetes study. J Clin Endocrinol Metabolism. 2020;105(4):e1549\u201360.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"10","key":"6461_CR49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/metabo10100391","volume":"10","author":"DN Rosaria Vincenza Giglio","year":"2020","unstructured":"Rosaria Vincenza Giglio DN, Giovanni Li Volti AP, Stoian. Liraglutide increases serum levels of MicroRNA-27b, -130a and\u2013\u2009210 in patients with type 2 diabetes mellitus: A novel epigenetic effect. Metabolites. 2020;10(10):391. https:\/\/doi.org\/10.3390\/metabo10100391.","journal-title":"Metabolites"},{"issue":"10","key":"6461_CR50","doi-asserted-by":"publisher","first-page":"e0186480","DOI":"10.1371\/journal.pone.0186480","volume":"12","author":"I Song","year":"2017","unstructured":"Song I, Roels S, Martens GA, Bouwens L. Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds. PLoS ONE. 2017;12(10):e0186480.","journal-title":"PLoS ONE"},{"issue":"3","key":"6461_CR51","doi-asserted-by":"publisher","first-page":"e0173576","DOI":"10.1371\/journal.pone.0173576","volume":"12","author":"J Li","year":"2017","unstructured":"Li J, Su L, Gong Y-y, Ding M-l, Hong S-b, Yu S, et al. Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1. PLoS ONE. 2017;12(3):e0173576.","journal-title":"PLoS ONE"},{"issue":"2","key":"6461_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/db17-0506","volume":"67","author":"S Jo","year":"2018","unstructured":"Jo S, Chen J, Xu G, Grayson TB, Thielen LA, Shalev A. miR-204 controls glucagon-like peptide 1 receptor expression and agonist function. Diabetes. 2018;67(2):256\u201364.","journal-title":"Diabetes"},{"key":"6461_CR53","first-page":"e6567","volume":"7","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Xiao X, Zheng J, Li M. A glucagon-like peptide-1 analog, Liraglutide, ameliorates endothelial dysfunction through MiRNAs to inhibit apoptosis in rats. PeerJ Biochem Biophys Molec Biol. 2019;7:e6567.","journal-title":"PeerJ Biochem Biophys Molec Biol"},{"key":"6461_CR54","doi-asserted-by":"crossref","unstructured":"Li R, Ye Z, She D, Fang P, Zong G, Hu K et al. Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120\/ABHD6. Drug Design, Development and Therapy. 2023:3557-72.","DOI":"10.2147\/DDDT.S384884"},{"key":"6461_CR55","doi-asserted-by":"crossref","unstructured":"Fang P, Ye Z, Li R, She D, Zong G, Zhang L et al. Glucagon-like peptide-1 receptor agonist protects against diabetic cardiomyopathy by modulating microRNA-29b-3p\/SLMAP. Drug Design, Development and Therapy. 2023:791\u2013806.","DOI":"10.2147\/DDDT.S400249"},{"key":"6461_CR56","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.12659\/MSM.906603","volume":"23","author":"J Li","year":"2017","unstructured":"Li J, Fu L-Z, Liu L, Xie F, Dai R-C. Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide alters bone marrow exosome-mediated MiRNA signal pathways in ovariectomized rats with type 2 diabetes. Med Sci Monitor: Int Med J Experimental Clin Res. 2017;23:5410.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"6461_CR57","doi-asserted-by":"crossref","unstructured":"Gaborit BJJ-B, Besbes S et al. Supplemental data from: glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: safe or not? The AngioSafe type 2 diabetes study. 2019.","DOI":"10.1210\/clinem\/dgz069"},{"issue":"19","key":"6461_CR58","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","volume":"375","author":"MM Redfield","year":"2016","unstructured":"Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868\u201377.","journal-title":"N Engl J Med"},{"issue":"1","key":"6461_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/STROKEAHA.116.013650","volume":"48","author":"S Dolz","year":"2017","unstructured":"Dolz S, G\u00f3rriz D, Tembl JI, S\u00e1nchez D, Fortea G, Parkhutik V, et al. Circulating MicroRNAs as novel biomarkers of stenosis progression in asymptomatic carotid stenosis. Stroke. 2017;48(1):10\u20136.","journal-title":"Stroke"},{"key":"6461_CR60","doi-asserted-by":"publisher","first-page":"107602962110579","DOI":"10.1177\/10760296211057903","volume":"27","author":"T Lu","year":"2021","unstructured":"Lu T, Li X, Long C, Ji W, Jiang L, Tian J. Circulating miR-27b as a biomarker of the development and progression of carotid artery stenosis. Clin Appl Thromb Hemost. 2021;27:10760296211057903.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"6461_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.metabol.2013.10.004","volume":"63","author":"L Sun","year":"2014","unstructured":"Sun L, Trajkovski M. MiR-27 orchestrates the transcriptional regulation of brown adipogenesis. Metabolism. 2014;63(2):272\u201382.","journal-title":"Metabolism"},{"issue":"10","key":"6461_CR62","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/nm.3361","volume":"19","author":"M Harms","year":"2013","unstructured":"Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19(10):1252\u201363.","journal-title":"Nat Med"},{"issue":"2","key":"6461_CR63","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1159\/000478071","volume":"42","author":"Q-W Jia","year":"2017","unstructured":"Jia Q-W, Chen Z-H, Ding X-Q, Liu J-Y, Ge P-C, An F-H, et al. Predictive effects of Circulating miR-221, miR-130a and miR-155 for coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem. 2017;42(2):808\u201323.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"6461_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/iub.427","volume":"63","author":"C Devlin","year":"2011","unstructured":"Devlin C, Greco S, Martelli F, Ivan M. miR-210: more than a silent player in hypoxia. IUBMB Life. 2011;63(2):94\u2013100.","journal-title":"IUBMB Life"},{"key":"6461_CR65","doi-asserted-by":"crossref","unstructured":"Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences. 2008;105(35):13027-32.","DOI":"10.1073\/pnas.0805038105"},{"issue":"2","key":"6461_CR66","doi-asserted-by":"publisher","first-page":"e13323","DOI":"10.1111\/apha.13323","volume":"227","author":"C Shi Jy, Chen","year":"2019","unstructured":"Shi Jy, Chen C, Xu X, Lu Q. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN\/AKT\/mTOR signalling pathway and suppressing autophagy. Acta Physiol. 2019;227(2):e13323.","journal-title":"Acta Physiol"},{"issue":"1","key":"6461_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01737-4","volume":"8","author":"Y Sassi","year":"2017","unstructured":"Sassi Y, Avramopoulos P, Ramanujam D, Gr\u00fcter L, Werfel S, Giosele S, et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017;8(1):1\u201311.","journal-title":"Nat Commun"},{"issue":"12","key":"6461_CR68","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.molmet.2015.09.012","volume":"4","author":"S Zhao","year":"2015","unstructured":"Zhao S, Poursharifi P, Mugabo Y, Levens EJ, Vivot K, Attane C, et al. \u03b1\/\u03b2-Hydrolase domain-6 and saturated long chain monoacylglycerol regulate insulin secretion promoted by both fuel and non-fuel stimuli. Mol Metabolism. 2015;4(12):940\u201350.","journal-title":"Mol Metabolism"},{"issue":"8","key":"6461_CR69","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/metabo12080761","volume":"12","author":"L-M Pusch","year":"2022","unstructured":"Pusch L-M, Riegler-Berket L, Oberer M, Zimmermann R, Taschler U. \u03b1\/\u03b2-Hydrolase Domain-Containing 6 (ABHD6)\u2014A multifunctional lipid hydrolase. Metabolites. 2022;12(8):761.","journal-title":"Metabolites"},{"issue":"1","key":"6461_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13098-023-01067-0","volume":"15","author":"K Bao","year":"2023","unstructured":"Bao K, Jiao Y, Xing L, Zhang F, Tian F. The role of Wnt signaling in diabetes-induced osteoporosis. Diabetol Metab Syndr. 2023;15(1):84.","journal-title":"Diabetol Metab Syndr"},{"key":"6461_CR71","doi-asserted-by":"publisher","first-page":"RP90437","DOI":"10.7554\/eLife.90437.3","volume":"12","author":"G Leanza","year":"2024","unstructured":"Leanza G, Cannata F, Faraj M, Pedone C, Viola V, Tramontana F, et al. Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength. Elife. 2024;12:RP90437.","journal-title":"Elife"},{"issue":"8","key":"6461_CR72","doi-asserted-by":"publisher","first-page":"e71895","DOI":"10.1371\/journal.pone.0071895","volume":"8","author":"X He","year":"2013","unstructured":"He X, Zhang W, Liao L, Fu X, Yu Q, Jin Y. Identification and characterization of MicroRNAs by high through-put sequencing in mesenchymal stem cells and bone tissue from mice of age-related osteoporosis. PLoS ONE. 2013;8(8):e71895.","journal-title":"PLoS ONE"},{"key":"6461_CR73","doi-asserted-by":"publisher","first-page":"117323","DOI":"10.1016\/j.bone.2024.117323","volume":"190","author":"S Minami","year":"2025","unstructured":"Minami S, Fujii Y, Yoshioka Y, Hatori A, Kaneko K, Ochiya T, et al. Extracellular vesicles from mouse bone marrow macrophages-derived osteoclasts treated with Zoledronic acid contain miR-146a-5p and miR-322-3p, which inhibit osteoclast function. Bone. 2025;190:117323.","journal-title":"Bone"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06461-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T16:01:41Z","timestamp":1745596901000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06461-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6461"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06461-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Declaration of AI-assisted technologies in the writing process: during the preparation of this review, the authors used ChatGPT to check the grammar and improve readability. After using the tools, we reviewed and edited the content as needed and took full responsibility for the content presented in the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"477"}}